We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 109

Fractured Myriad Genetics ruling follows SCOTUS remand
  • Shook Hardy & Bacon LLP
  • USA
  • August 30 2012

Ruling that one plaintiff had standing to seek a declaratory judgment as to the patent eligibility of certain genetic discoveries, the Federal Circuit Court of Appeals has once again reversed in part and affirmed in part a lower court’s determination that isolated DNA molecules and methods of comparing molecules to determine whether a patient’s genes have mutations that could cause breast and ovarian cancer were not patent eligible


Biosimilars market expected to increase by billions over next four years
  • Shook Hardy & Bacon LLP
  • USA
  • April 7 2011

Market analysts have apparently forecast huge growth in the market for biosimilars due to the upcoming loss of patent exclusivity for a number of branded drugs


News Bytes - July 11, 2013
  • Shook Hardy & Bacon LLP
  • USA
  • July 11 2013

The White House issues its "2013 Joint Strategic Plan on Intellectual Property Enforcement." Among other things, the plan calls for an increased


News Bytes - June 6, 2013
  • Shook Hardy & Bacon LLP
  • USA
  • June 6 2013

The U.S. Patent and Trademark Office creates the After Final Consideration Pilot Program 2.0 which modifies and extends a program designed to


Genetic technologies settles infringement suit over non-DNA coding technology
  • Shook Hardy & Bacon LLP
  • USA
  • May 2 2013

Genetic Technologies Ltd. (GTG) has reportedly settled a patent infringement lawsuit filed in late 2012 against PreventionGenetics. While the terms


Biosimilar development costs may affect savings potential
  • Shook Hardy & Bacon LLP
  • USA
  • January 30 2014

According to Pharm Exec Senior Editor Ben Comer, the biosimilars that were supposed to save consumers and taxpayers money as "the first wave of


News Bytes
  • Shook Hardy & Bacon LLP
  • USA
  • February 13 2014

The U.S. Patent and Trademark Office requests comments by March 3, 2014, on the revision of a previously approved information collec- tion concerning


News Bytes
  • Shook Hardy & Bacon LLP
  • USA
  • February 27 2014

The U.S. Food and Drug Administration requests comments on the estimated time burdens of a proposed study that "will investigate the impact of


Australian court finds human gene mutation to be patentable
  • Shook Hardy & Bacon LLP
  • Australia, USA
  • September 11 2014

A full panel of the Federal Court of Australia has upheld its earlier ruling that an isolated but naturally occurring nucleic acid, BRCA1, can be


News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • September 11 2014

The U.S. Patent and Trademark Office (USPTO) seeks comments on the estimated time burdens of revisions to a currently approved information collection